



QEUH - SCOTTISH TDM SERVICE - VEDOLIZUMAB (ENTYVIO) REQUEST

Please complete each question either by ticking a box or completing the open text box with a comment. Please forward completed form and sample to: -

Dr Peter Galloway, Consultant Clinical Biochemist, Laboratory Building, QEUH, G51 4TF

Patient Label

DATE OF TEST

___/___/___

DATE OF FIRST VEDOLIZUMAB DOSE

___/___/___

DATE OF LAST VEDOLIZUMAB DOSE

___/___/___

SPECIALIST NURSE/CONSULTANT RESPONSIBLE: _____

HOSPITAL: _____

1) PRIMARY INDICATION FOR DRUG PRESCRIPTION

- ULCERATIVE COLITIS
- CROHNS DISEASE
- IBD UNCLASSIFIED
- OTHER GASTROINTESTINAL

2) DRUG DOSE

- 300MG
- OTHER

3) DOSING FREQUENCY

- 8 WEEKLY
- 6 WEEKLY
- 4 WEEKLY
- OTHER

4) CONCOMITANT IMMUNOSUPPRESSION (AND DOSE)

- | | |
|---|---|
| <input type="checkbox"/> AZATHIOPRINE _____MG | <input type="checkbox"/> PREDNISOLONE _____MG |
| <input type="checkbox"/> MERCAPTOPYRINE _____MG | <input type="checkbox"/> METHOTREXATE _____MG |
| <input type="checkbox"/> OTHER <input type="text"/> | |

5) INDICATION FOR TEST

- | | |
|---|--|
| <input type="checkbox"/> PRIMARY NON-RESPONSE | <input type="checkbox"/> EARLY INDUCTION (WEEK 6 PRE-INFUSION TROUGH) |
| <input type="checkbox"/> SECONDARY LOSS OF RESPONSE | <input type="checkbox"/> END OF INDUCTION (RESPONDING TO TREATMENT) |
| <input type="checkbox"/> POST DOSE-ADJUSTMENT | <input type="checkbox"/> PLANNED TREATMENT REVIEW (RESPONDING TO TREATMENT) |
| <input type="checkbox"/> OTHER <input type="text"/> | |

6) ADDITIONAL INFORMATION

Please use this free text box to supply further relevant information

NB - THERE IS CURRENTLY LIMITED EVIDENCE TO SUPPORT THE CLINICAL USE OF VEDOLIZUMAB TDM AND TARGET DRUG CONCENTRATIONS HAVE NOT BEEN ESTABLISHED. RESULTS WILL BE PUBLISHED WITHOUT A SPECIFIED THERAPEUTIC RANGE WITH A TARGET TURNAROUND TIME OF 4 WEEKS (DEPENDENT ON VOLUME OF SAMPLES). THE VEDOLIZUMAB ASSAY HAS BEEN FULLY VALIDATED EXTERNALLY. SAMPLES RECEIVED WILL CONTRIBUTE TO THE UNDERSTANDING AND INTERPRETATION OF VEDOLIZUMAB DRUG AND ANTIBODY RESULTS.